Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|14|7|659-670

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.14, Iss.7, 2014-09, pp. : 659-670

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alternating R‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 110-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mean platelet volume predicts prognosis in patients with diffuse large B‐cell lymphoma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 104-109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of patients older than 80 years with diffuse large B‐cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma

By Fabbri Alberto   Cencini Emanuele   Bocchia Monica  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3746-3747

Blackwell Publishing

Access to resources Recommend Favorite

Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

By Williams Jessica N.   Koff Jean L.   Flowers Christopher R.  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3748-3748

Blackwell Publishing

Access to resources Recommend Favorite